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Vasoactive agents which elevate either cGMP or cAMP 
inhibit platelet activation by pathways sharing at least 
one component, the 46/50 kDa vasodilator-stimulated 
phosphoprotein (V ASP). V ASP is stoichiometrically 
phosphorylated by both cGMP-dependent and cAMP-
dependent protein kinases in intact human platelets, and 
its phosphorylation correlates very well with platelet 
inhibition caused by cGMP- and cAMP-elevating agents. 
Here we report that in human platelets spread on glass, 
V ASP is associated predominantly with the distal parts 
of radial micro filament bundles and with microfilaments 
outlining the periphery, whereas less V ASP is associated 
with a central microfilamentous ring. V ASP is also 
detectable in a variety of different cell types including 
fibroblasts and epithelial cells. In fibroblasts, V ASP is 
concentrated at focal contact areas, along microfilament 
bundles (stress fibres) in a punctate pattern, in the 
periphery of protruding lamellae, and is phosphorylated 
by cGMP- and cAMP-dependent protein kinases in 
response to appropriate stimuli. Evidence for the direct 
binding of V ASP to F -actin is also presented. The data 
demonstrate that V ASP is a novel phosphoprotein 
associated with actin filaments and focal contact areas, 
i.e. transmembrane junctions between microfilaments 
and the extracellular matrix. 
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Introduction 
Numerous vasoactive agents regulate human platelet 
activation. Platelet agonists such as thrombin, thromboxane 
Az, platelet activating factor, collagen and ADP elevate 
intracellular free Ca2+, activate myosin light chain kinase, 
protein kinase C and protein tyrosine kinases, and platelet 
activation ultimately results in shape change, adhesion, 
aggregation and degranulation (Haslam, 1987; Siess, 1989; 
Rink and Sage, 1990). In contrast, many physiologically and 
pharmacologically important platelet inhibitors such as 
prostacyclin and endothelium-derived relaxing factor 
(EDRF) elevate platelet levels of cAMP, cGMP or both, 
activate cAMP- and/or cGMP-dependent protein kinases 
(cAMP-PK, cGMP-PK) and inhibit platelet activation by 
agonists (Walter, 1989; Walter et al., 1991). The two cyclic 
nucleotides cAMP and cGMP may have distinct but also 
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common sites of action in human platelets. Cyclic nucleotide-
induced inhibition of platelet activation apparently involves 
an early step of the activation cascade such as inhibition of 
phospholipase C and subsequent Ca2+ discharge from 
intracellular stores (Siess, 1989; Rink and Sage, 1990; 
WaIter et al. , 1991; Geiger et al., 1992). Alternatively, 
Caz +-ATPases, myosin light chain kinase (Walter, 1989; 
WaIter et al., 1991) and cytoskeletal elements (Fox, 1987; 
Zhang et al., 1988; Chen and Stracher, 1989; Fox and 
Berndt, 1989; Siess, 1989) have also been considered as 
potential targets , but the precise mechanism of action of 
cyclic nucleotide-elevating platelet inhibitors is not very well 
understood. 
Recently, we purified and characterized a 46/50 kDa 
vasodilator-stimulated phosphoprotein (V ASP) which is 
stoichiometrically phosphorylated by cAMP- or cGMP-
dependent protein kinase in experiments with purified 
proteins as well as in intact human platelets treated with 
cAMP- or cGMP-elevating platelet inhibitors, respectively 
(Waldmann et al., 1986, 1987; Halbriigge and Walter, 1989; 
Halbriigge et al., 1990) . VASP phosphorylation at one site 
by either protein kinase alters the properties of the protein 
in SOS - PAGE causing a shift in its apparent molecular mass 
from 46 to 50 kDa (Halbriigge and Waiter, 1989). This 
phosphorylation-induced change in the apparent molecular 
mass of V ASP has recently been used for the quantitative 
analysis ofVASP phosphorylation in intact cells (Halbriigge 
et al., 1990; Nolte et al., 199Ia,b). 
V ASP phosphorylation correlates very well with 
vasodilator-induced inhibition of platelet activation 
(Waldmann et al., 1987; Halbriigge et al., 1990; Siess and 
Lapetina, 1990; WaIter et al., 1991); however, the precise 
functional role of V ASP has not been elucidated. Recently, 
the presence and regulation of V ASP phosphorylation was 
also discovered in other human cell types including 
Iymphocytes and granulocytes (Halbriigge et al., 1992) . 
Because of the potential importance of this 46/50 kDa 
phosphoprotein V ASP for signal transduction pathways 
regulated by both cAMP- and cGMP-elevating hormones 
and vasoactive agents , we have now investigated the 
subcellular distribution of V ASP in human platelets and a 
variety of other cell types. Evidence will be presented that 
V ASP is a novel phosphoprotein associated with actin 
filaments and focal contact areas. Our data suggest these 
cellular structures and their associated proteins as potential 
targets for regulation by cAMP- and cGMP-dependent 
protein kinases . 
Results 
Characterization of VASP antiserum M4 
In immunoblots of platelet and fibroblast homogenates, a 
polyclonal rabbit antiserum raised against purified V ASP 
(M4) specifically recognized a polypeptide doublet of 46/50 
kDa (Figure 1, lanes 3-4). The 46 kDa VASP shifts to a 
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Fig. 1. Specificity of antiserum against V ASP (M4) in immunoblots. 
Proteins in homogenates of human platelets (lanes I and 2: 135 p.g; 
lane 3: 50 p.g) and human dermal fibroblasts (lane 4: 200 p.g) were 
probed with either affinity-purified M4 (lane I) , preadsorbed affinity-
purified M4 (lane 2) or original M4 anti-VASP (lanes 3-4) . 
Molecular masses (in Da) of standard proteins are indicated at the 
right margin. VASP (a closely spaced doublet with apparent molecular 
masses of 46 and 50 kDa) is specifically recognized by M4 and 
affinity-purified M4. 
protein with apparent molecular mass of 50 kDa in 
SOS - PAGE when one specific site is phosphorylated by 
cAMP- or cGMP-dependent protein kinases (Halbriigge and 
Walter, 1989). Thus, the 46 kDa and 50 kDa protein bands 
recognized by antiserum M4 represent dephospho- and 
phosphoforms of V ASP with respect to this particular 
phosphorylation site (Halbriigge et al., 1990) and will 
subsequently be referred to as dephospho- and phospho-
V ASP, respectively , although V ASP contains additional 
phosphorylation sites which were not analysed here . 
Imrnunoblotting experiments with antiserum M4 and affinity-
purified M4 gave identical results (Figure 1, lanes 1, 3 and 
4). Moreover, the patterns of subcellular V ASP distribution 
obtained by immunofluorescence were identical with 
antiserum M4 and affinity-purified M4, whereas preimmune 
serum was negative (not shown). When affinity-purified M4 
was preincubated with the 46/50 kOa area of nitrocellulose 
sheets to which platelet homogenate proteins had been 
transferred after SOS - PAGE, its V ASP-staining capacity 
was completely lost as assayed by immunoblots (Figure 1, 
lane 2) or by indirect immunofluorescence (not shown) . 
These results demonstrated that M4, used as complete serum 
or after affinity purification, selectively recognized V ASP 
in its SOS-denatured form as well as in situ . 
Localization of VASP to microfilaments and focal 
contact areas 
Platelets that are allowed to settle onto coverslips adhere and 
begin to extrude pseudopods (Zobel and Woods, 1983; 
Behnke and Bray, 1988). These pseudopods have been 
shown to contain microfilament bundles (Debus et al. , 1981) 
and their distal portions coincide with areas of firm 
2064 
attachment to the underlying substratum (focal contacts; 
Zobel and Woods, 1983; Alexandrova and Vasiliev, 1984). 
Staining of spreading and fully spread platelets for actin 
shows three main areas of fluorescence , i.e. the radial 
microfIlament bundles , the rim of the veil-like lamellae 
spread out between such bundles (Oebus et al. , 1981 ; 
Figure 2a' -e'), and , in some platelets, a ring-like structure 
in the centre of the platelet (Figure 2e') . Indirect 
immunofluorescence with antiserum M4 showed V ASP 
concentrated in two of these structures, the terminal portions 
of radial micro filament bundles and the peripheral 
microfilaments of veils (Figure 2a -e) . The central ring, 
which in fully spread platelets appeared as an area of very 
prominent actin staining, was labelled less intensely and less 
homogeneously with M4, revealing a dotted distribution of 
V ASP (Figure 2e and e'). 
M4 also revealed the expression and subcellular 
distribution of V ASP in tissue culture cells. In analogy to 
the staining patterns of adhering platelets, V ASP appeared 
to be highly concentrated at the terminal portions of 
microftlament bundles (stress fibres) of stationary fibroblasts 
derived from man or rat , respectively (Figure 3a -t), and 
also at the peripheral regions of the protruding lamellae 
developed by locomoting or spreading cells, especially in 
ruffling areas (Figure 3d). In addition, well spread fibroblasts 
showed a distinct, quite regular distribution of V ASP as 
periodically arranged dots along their stress fibres 
(Figure 3a, e and t) . 
Expression of VASP in different cell types 
The expression of V ASP was analysed by immunoblotting 
of homogenates from different blood and tissue culture cells 
and also by indirect immunofluorescence (Table I) . With 
regard to human cells, V ASP was found not only in platelets 
and differentiated blood cells like granulocytes and 
lymphocytes, but also in their tumour derivatives, leukaemia 
(HEL 92 .1.7, HL-60 and K -562) and lymphoblastoma (HuT 
78 , Jurkat, Raji and U-937) cells. V ASP was also located 
in certain tissue-forming cells analysed (endothelial cells , 
vascular smooth muscle cells and fibroblasts) and in cell lines 
derived from such cells (neuroblastoma - glioma hybrid cells 
N x G 108CC15 and epithelial cells A-431, LLC-PK1 , BHK 
and PtK2). In addition , prominent VASP staining was 
detected at the site of intercalated discs of rat heart (data 
not shown) . 
Although the content of V ASP in different cells has not 
been exactly quantified, a rough estimate derived from a 
comparison of lanes 3 and 4 in Figure 1 suggests that there 
is - 5- to 8-fold more V ASP per mg of homogenate in 
platelets than in human dermal fibroblasts . Platelets have 
been shown previously to contain 2.45 p,g/mg VASP 
(Halbriigge and Waiter , 1990) . Like fibroblasts , other cell 
types of human origin so far investigated contained less 
VASP than platelets (Halbriigge et al., 1992). 
Phosphorylation of VASP in intact human fibroblasts 
in response to prostaglandin E1 (PG-E1) and a cGMP-
analogue 
The demonstration of V ASP as part of the microfIlamentous 
system not only in platelets but also in fib rob lasts raised the 
question of whether V ASP is phosphorylated by cAMP- and 
cGMP-dependent protein kinases in intact fibroblasts , as has 
Protein associated with actin filaments and focal contacts 
Fig. 2. Comparison of subcellular distribution of VASP and F-actin in human platelets spread on glass. Localization of VASP (a -e) and F-actin 
(a' -e') was revealed by double labelling, i.e. indirect immunofluorescence and NBD-phallacidin staining, respectively . (a and a') : Overview, 
showing a population of platelets in different stages of spreading, with intense VASP staining of radial microfilament bundles. (b,b' -e,e'): Selected 
views of individual platelets in consecutive stages of spreading. (b and b'): Partially spread platelet. Microfilament bundles are arranged in spikes that 
stain for actin and VASP (arrows) , but the lamella has not reached the tips of these bundles. (c and c' and d and d'): Later stages in spreading. The 
lamella has extended to the distal portions of the radial microfilament bundles, VASP is co-localized with actin at the periphery (arrowheads in c,c'). 
Staining of the fully extended microfilament bundles is mostly confined to their distal portions, as is especially evident in d and d'. (e and e'): Fully 
spread platelet. The lamella has engulfed the microfilament bundles (arrowheads). In addition to the presence of actin in radial bundles and the 
peripheral regions of the lamella, actin filaments are organized in a central ring (long arrow in e'). This structure is not homogeneously decorated by 
M4. Bar in a', valid for a and a': 10 I'm. Bar in c', valid for b,b'-e,e' : 5 I'm. 
already been demonstrated for platelets (Waldmann et al. , 
1987; Halbriigge et al., 1990). Therefore, the state ofVASP 
phosphorylation was determined in homogenates of human 
dermal fibroblasts which had been incubated with either PG-
El or with 8-(4-chlorophenylthio)-guanosine-3' ,5'cyclic 
monophosphate (8-pCPT -cGMP). PG-El was chosen since 
this prostaglandin raises cAMP in many cell types including 
fibroblasts (Smith, 1989) and causes VASP phosphorylation 
mediated by cAMP-PK in platelets and lymphocytes 
(Halbriigge et al., 1990, 1992). 8-pCPT-cGMP was chosen 
since this cell membrane permeant cGMP-analogue is a 
selective cGMP-PK activator which has no major effects on 
other protein kinases or phosphodiesterases and which was 
shown to cause V ASP phosphorylation mediated by cGMP-
PK in platelets (Geiger et al., 1992). After a 5 min 
incubation of fibroblasts with 5 JLM PG-Eh almost all of 
V ASP was converted from the 46 kDa dephosphoform to 
the 50 kDa phosphoform, whereas a 30 min incubation with 
8-pCPT -cGMP shifted about half of V ASP to its 50 kDa 
phosphoform (Figure 4). Incubation with a combination of 
PG-El and 8-pCPT-cGMP was no more effective than PG-
El alone (Figure 4). The fluorescence analysis of VASP 
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Fig. 3. Comparison of the subcellular distribution of VASP (a-f, revealed by M4 staining) and F-actin (a' -d' , decorated with NBD-phallacidin), 
respectively , in rat (a,a' -c,c', e and I) and human (d and d') fibroblasts. All comparisons (a ,a ' -d,d ' ) were made with double fluorescence. VASP 
is highly concentrated in virtually all focal adhesion sites of well spread stationary fibroblasts, at the periphery (a ,a' -c,c') as well as at the ventral 
membrane (c and c'). In addition, stress fibres show anti-VASP decoration in distinct periodicities in their proximal portions (e and I). (d and d'): 
Locomoting or spreading fibroblast, showing VASP and F-actin co-localized in the ruffling periphery of a protruding lamella (arrowheads). Bar in a' 
(valid for a,a' -c,c', e and I), 10 I'm; bar in d' (valid for d and d'), 20 I'm. 
distribution and actin organization did not reveal any 
dramatic differences between controls and cells treated with 
either PG-E) or 8-pCPT-cGMP (not shown). Also, 
conditions which affected the phosphorylation state of V ASP 
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(e.g. treatment of cells with PG-E) and 8-pCPT-cGMP) did 
not alter the Triton X-lOO solubility of VASP since VASP 
was recovered nearly quantitatively in the soluble fraction 
of both control and treated cells (not shown). 
Table I. Detection of V ASP in different cell types by immunoblotting 
or indirect immunofluorescence 
Cell type 
Primary cells and tissues 
Platelets (human) 
Lymphocytes (human)" 
Granulocytes (human)" 
Endothelial cells (human)" 
Dermal fib rob lasts (human) 
Muscle tibroblasts (rat) 
Embryo fibroblasts (chicken) 
Vascular smooth muscle cells 
(porcine)b 
Heart (rat)b 
Cell lines 
Human" 
HEL 92.1.7 
HL-60 
lurkat 
K-562 
U-937 
HuT 78 
Raji 
A-43 I 
Porcine 
LLC-PKI 
Rodent 
BHK 
NxG 108CCI5 
Marsupial 
PtK2 
Immunoblot Immunofluorescence 
+ + 
+ n.d. 
+ n.d. 
+ + 
+ + 
+ + 
n.d. + 
+ + 
n.d. + 
+ n.d. 
+ n.d. 
+ n.d . 
+ n.d. 
+ n.d. 
+ n.d. 
+ n.d. 
+ n.d. 
+ + 
+ + 
+ n.d. 
+ + 
+, presence of 46/50 kDa VASP in immunoblots or observation of 
typical immunotluorescene pattern, respectively 
n.d., not determined 
" Halbriigge et al., 1992 
b K.Abel, T.Markert and U.Walter, unpublished experiments 
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Fig. 4. Autoradiograph showing the phosphorylation of VASP in intact 
human fibroblasts. Monolayers of fibroblasts were incubated with 
buffer (control), 5 I'M PG-El for 5 min, 0.47 mM 8-pCPT-cGMP for 
30 min, and with both 5 I'M PGE I and 0.47 mM 8-pCPT-cGMP (25 
min with the cGMP-analogue alone followed by a 5 min incubation 
with the analogue + PG-El) as indicated. Fibroblasts were harvested 
in SDS sample buffer and analysed for V ASP phosphorylation by 
immunoblotting. The shift of the apparent molecular mass from 46 to 
50 kDa indicates phosphorylation of VASP. 
Cosedimentation of VASP with F-actin 
The co-localization of V ASP with microfilaments, as 
revealed by indirect immunofluorescence, prompted the 
question of whether V ASP binds directly to F-actin . To 
address this question, purified V ASP and F-actin were co-
Protein associated with actin filaments and focal contacts 
VN3P 
Actin 
Origin 
VN3P 
Actin 
Dye front -
s 
+ 
P s 
+ 
+ 
P 
+ 
s 
... -
P 
Fig. 5. Binding of V ASP to F-actin in a cosedimentation assay. V ASP 
and F-actin were mixed (final concentrations: 110 I'g/ml VASP, 500 
I'g/ml actin), incubated for 30 min at room temperature and then 
centrifuged at 100 000 g for 2 h. Equivalent amounts of supernatants 
(S) and resuspended pellets (P) were separated by SDS - PAGE and 
stained with Coomassie blue. The composition of the samples analysed 
is indicated at the top of each lane. 
incubated for 30 min at room temperature, and the mixture 
was subsequently centrifuged at 100 000 g for 2 h. F-Actin 
was pelleted nearly quantitatively by this high speed 
centrifugation, and a major part of total VASP co-sedimented 
with F-actin, whereas in the absence of F-actin no VASP 
was detected in the 'pellet' fraction (Figure 5). Interestingly, 
the ratio of the 46 kDa and 50 kDa forms of V ASP found 
in the F-actin pellet was similar to that found in the 
supernatant (Figure 5), suggesting that both the 46 and 50 
kDa forms of V ASP cosedimented equally well with F-actin, 
It is unlikely that the cosedimentation of actin and V ASP 
was due to contaminating proteins since the preparations of 
both actin and V ASP were > 95 % pure and since no 
contaminating proteins (which could have mediated V ASP 
binding to F-actin) were observed in the pellet fractions when 
analysed by SDS-PAGE and Coomassie blue staining 
(Figure 5), However, our findings do not exclude the 
possibility that, in cells, the association of V ASP with actin 
filaments is mediated by an interaction with other 
components, 
Discussion 
VASP is a novel actin filament- and focal contact-
associated protein 
The results of this study together with our published 
biochemical data indicate that V ASP, a substrate for cAMP-
as well as cGMP-dependent protein kinases, is a widely 
distributed, novel protein associated with actin fIlaments and 
focal contact areas, Many actin-binding proteins have already 
been described (Vandekerckhove, 1990; Hartwig and 
Kwiatkowski, 1991), some of which have an apparent 
molecular mass similar to that of V ASP in SDS - PAGE. 
Therefore, it has to be considered whether V ASP may be 
identical to one of these or related proteins, in particular 
tropomodulin, band 4,9 or a 53 kDa actin fIlament bundling 
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protein from porcine brain. In contrast to V ASP, 
tropomodulin is not a substrate for cAMP-PK (Fowler, 
1987) , nor does it bind to F-actin (Fowler, 1990). VASP 
and band 4.9 differ with respect to their Triton X-lOO 
solubility (this study ; Faquin et al. , 1988) and their 
properties as protein kinase C substrates (Home et al., 1985 ; 
Palfrey and Waseem, 1985; Faquin et al. , 1986, 1988; 
Waldmann et al. , 1987). Furthermore, the hydrodynamic 
properties of V ASP indicate a highly asymmetrical structure 
(unpublished results) and differ from the hydrodynamic 
properties reported for tropomodulin (Fowler, 1987), band 
4.9 (Siegel and Branton, 1985) and the 53 kDa actin ftlament 
bundling protein from porcine brain (Maekawa et al., 1983). 
Sasaki et al. (1990) purified a 48 kDa protein from platelets 
which bound to an actin - Sepharose column; however, the 
limited data available on this protein do not allow a direct 
comparison with V ASP. 
Our recent, unpublished data strongly indicate that V ASP 
differs not only from biochemically characterized actin 
ftiament- and focal contact-associated proteins, but also from 
all proteins with established primary structure. Comparison 
of partial V ASP sequences (obtained from protein 
microsequences and a partial cDNA clone) to sequences 
currently available in nucleic acid and protein databases , 
revealed no identity with any protein (C.Haffner et al., 
unpublished results), including the 47 kDa N-terminal 
proteolytic fragment of talin (Rees et al., 1990) . 
The immunofluorescence analyses reported here 
demonstrate that V ASP is associated with the microfilament 
system of a wide variety of cell types. Like VASP, several 
other microfilament proteins such as talin (Burridge and 
Connell , 1983a,b) and a-actinin (Lazarides and Burridge, 
1975) were also found to be concentrated at focal adhesion 
sites , i.e . at cell- matrix junctions , and in the cortical actin 
filament webs at the periphery of highly dynamic lamellae. 
VASP is also present in cell-cell contacts (unpublished). 
This concentration in cell- matrix as well as in cell- cell 
junctions, together with the distinct and periodical 
localization of V ASP in stress fibres (which contain 
microfilament proteins arranged in sarcomere-like units) is 
especially reminescent of the distribution of a-actinin. 
Indeed, we found that these V ASP-positive spots, like a-
actinin (Sanger et al., 1983) , showed a cell-line specific 
spacing, and double labelling with antibodies against V ASP 
and a-actinin produced superimposable patterns of 
immunofluorescence (unpublished observations) . However, 
there are also differences in the intracellular localization of 
these two proteins. In particular, the intracellular localization 
of V ASP in spread platelets (this study) differs from that 
of a-actinin (Debus et al., 1981), and V ASP is not associated 
with the cleavage furrow in mitotic cells or with the 
peripheral belt of epithelial cells (unpublished), whereas all 
these structures have been found to contain a-actinin 
(Fujiwara et al., 1978; Sanger et al. , 1987; Schulze et al ., 
1989). 
Phosphorylation of VASP by cAMP- and cGMP-
dependent protein kinases in fibroblasts 
Analysis of the phosphorylation-induced change in V ASP 
mobility in SDS - PAGE was used to determine the state of 
V ASP phosphorylation in intact human fibroblasts . In 
addition , the effects of agents which have been shown 
(Halbriigge et al., 1990; Geiger et al. , 1992) to activate 
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selectively either cAMP-PK (e.g. PG-El) or cGMP-PK 
(e .g. 8-pCPT-cGMP) were analysed. As demonstrated in 
Figure 4 , activation of cAMP-PK by PG-El converted 
V ASP almost quantitatively from the 46 kDa dephosphoform 
to the 50 kDa phosphoform, whereas maximal V ASP 
phosphorylation due to activation of cGMP-PK by 8-pCPT-
cGMP was - 50%. These data not only demonstrate V ASP 
phosphorylation in intact fib rob lasts , but also provide 
functional evidence for the presence and regulation of cGMP-
PK in these cells. The latter is not trivial since the limited 
expression and cellular distribution of cGMP-PK, as well 
as low cellular concentrations of cGMP-PK, have hindered 
investigations of the physiological role of this kinase (Walter, 
1989). Only preliminary immunocytochemical experiments 
(Walter, 1989) had suggested that fibroblasts may contain 
type I cGMP-PK. 
Appropriate elevation of cAMP-PK activity in fibroblasts 
and epithelial cells is known to result in reversible disruption 
of stress fibres (Lamb et al. , 1988; Roger et al., 1988; 
Turner et at. , 1989) and in the loss of talin and vinculin from 
focal contacts (Turner et al., 1989). The phosphorylation 
and concomitant inhibition of myosin light chain kinase by 
cAMP-PK is thought to be of fundamental importance for 
the observed breakdown of the cellular actin skeleton (Lamb 
et al., 1988; Fernandez et al., 1990). However, the cAMP-
PK-mediated phosphorylation of VASP in fibroblasts 
described in this study is nearly quantitative and complete 
after a 5 min incubation with PG-El , i.e. under conditions 
where major alterations of the actin skeleton are not 
detectable. Also, cGMP-PK-mediated V ASP phosphoryl-
ation was not accompanied by gross morphological 
alterations in the cells studied. 
Alternatively, V ASP phosphorylation may have functional 
consequences other than structural changes of the actin 
cytoskeleton. Cyclic nucleotide elevating agents which 
stimulate V ASP phosphorylation in human platelets 
concomitantly inhibit both the protein kinases (myosin light 
chain kinase and protein kinase C) and the Ca2+ 
mobilization associated with platelet activation (Waldmann 
et al., 1987; Waiter, 1989; Halbriigge et al., 1990; Nolte 
et al. , 1991a,b; Geiger et al. , 1992). This multifocal 
inhibition would be easiest to achieve if phospho-V ASP 
inhibited an early step of platelet activation, e .g . at the level 
of phospholipase C (WaIter, 1989; WaIter et al., 1991 ; 
Geiger et al., 1992). Furthermore, our present evidence 
demonstrating a cytoskeletal association of V ASP would 
position V ASP at a site which is perhaps critical for 
regulation of phospholipase C. Recently , thrombin activation 
of platelets was shown to increase the total cytoskeleton 
associated enzyme activities of phospholipase C, inositol-
lipid kinases and diacylglycerol kinase (Grondin et al., 
1991). A similar cytoskeleton association and regulation of 
such enzyme activities involved in lipid metabolism has been 
reported for EGF-treated A-431 cells (Payrastre et al., 
1991). Therefore, the cytoskeleton, and in particular 
cytoskeleton anchorage sites at the plasma membrane, are 
prominent candidates for forming a matrix for close contacts 
between various signal transduction components (Grondin 
et al., 1991 ; Payrastre et al. , 1991) modulated by 
phosphorylation . Future work will have to clarify the 
functional role of V ASP phosphorylation and the 
physiological significance of the specific association of V ASP 
with actin filaments and focal contact areas. 
Materials and methods 
Cells 
Human dermal fibroblasts, kindly provided by Dr Hiihn (Department of 
Human Genetics, University of Wiirzburg, FRG), were cultured in 
Dulbecco's modified Eagle's medium (DMEM, Gibco BRL, Eggenstein, 
FRG) supplemented with 10% fetal calf serum (FCS, Gibco BRL) and used 
as passages 7 -12 for experiments. Rat muscle fibroblasts (Schulze et al., 
1989) and chicken embryo fibroblasts (Westmeyer et al., 1990) were cultured 
as described. BHK and PtK2 cells were cultured in DMEM supplemented 
with 10% FCS. LLC-PKI cells were grown in minimal essential medium 
(MEM, Gibco BRL) supplemented with 7.5% FCS. Culture media were 
supplemented with I % antibiotic-antimycotic solution (Sigma, Deisenhofen, 
FRG). All cells were cultured at 3rC with 5 % CO2, 
Experiments with fibroblasts 
Human dermal fibroblasts were grown for 2 - 3 days in 58 x 15 mm tissue 
culture dishes (Nunc, Wiesbaden-Biebrich, FRG) until they reached a density 
of 0.7 -2.0 x 104 cells/cm2 For immunofluorescence analysis, cells were 
grown in parallel on coverslips. One hour prior to experiments, cells were 
incubated with a medium containing 10 JLM indomethacin in order to inhibit 
endogenous prostaglandin synthesis . Cells were incubated at 3rC with 5 JLM 
PG-El (Sigma) and/or 470 JLM 8-pCPT-cGMP (BioLog, Bremen, FRG) 
for 5 min or 30 min, respectively . Agents examined were added to the cells 
in phosphate buffered saline (PBS, 10 mM sodium phosphate pH 7 .4, 150 
mM NaCI) supplemented with 1 mM CaCI2, 2 mM MgCI2 and 10 JLM 
indomethacin. Cells incubated with the vehicle medium alone were used 
as controls. At the end of incubations, cells were lysed in SDS sample buffer 
or fixed for immunofluorescence as indicated below. 
Antiserum 
M4 rabbit antiserum against human V ASP was raised as described previously 
(Halbtiigge et al. , 1990). Affinity-purified M4 was prepared by adsorption 
and elution of antibodies using protein antigens immobilized on nitrocellulose 
blots essentially as described (Smith and Fisher, 1984). In short, antiserum 
M4 (600 JLI , diluted I: 10 in PBS, 0.5% Tween 20) was adsorbed to the 
46/50 kDa area of a nitrocellulose sheet to which platelet homogenate proteins 
(I. I mg) separated by SDS - PAGE had been transferred . Antibodies were 
eluted from nitrocellulose strips by three successive 30 s washes (1.5 ml 
each) with glycine-HCI buffer, pH 2.3. This eluate, which was immediately 
neutralized by the addition of 0.25 vol of 250 mM sodium phosphate , is 
referred to as 'affinity-purified M4 '. An aliquot of affinity-purified M4 (37 
JLI), diluted 1:60 in buffer A (PBS, 0 .5% Tween 20, lOO JLg/ml BSA, 0 .01 % 
NaN3), was successively preadsorbed to the 46/50 kDa area of four 
different nitrocellulose blots of platelet homogenate proteins (2.3 mg per 
sheet) for several hours each. This solution depleted of VASP antibodies 
was used for control immunofluorescence and immunoblot experiments. 
Fluorescent staining of cells 
Cells grown on coverslips were fixed in 3.7% formaldehyde for 20 min 
on ice, perrneabilized by 0.2% Triton X-lOO in PBS for 10 min and incubated 
for 30 min at room temperature with M4 (diluted 1:500 in PBS) or affinity-
purified M4 (diluted 1:60 in buffer A). Affinity-purified M4, preadsorbed 
as described above, was used without further dilution. Subsequently, cells 
were incubated for 30 min at room temperature with 4.3 JLg/m1 rhodamine-
conjugated affinity-purified donkey anti-rabbit IgG (Dianova, Hamburg, 
FRG) and, where indicated, with -0.33 JLM NBD-phallacidin (Molecular 
Probes, Eugene, OR, USA). Cells were washed repeatedly with PBS between 
individual incubation steps. 
For immunofluorescence studies with platelets, venous blood from healthy 
volunteers was collected into 5 mI coagulation tubes (Monovette SNC; 
Sarstedt, Miimbrecht, FRG) and centrifuged for 15 min at 360 g. The 
supematant (platelet rich plasma) was placed onto ethanol-cleaned glass 
coverslips (Superior, Bad Mergentheim, FRG). Platelets were allowed to 
settle and spread for 30-40 min in a moist chamber at room temperature. 
Platelets not attached were removed by rinsing the covers lips twice with 
PBS. In some cases, platelet rich plasma was diluted I :20 with HEPES 
buffer (10 mM HEPES pH 7.4, 145 mM NaCI, 5 mM KCI , 1 mM MgCI2' 
10 mM glucose) and coverslips were rinsed twice and incubated for 5 min 
at 37°C in the same buffer prior to fixation. Spread platelets were fixed 
and perrneabilized by sequential incubation with 3.7 % formaldehyde in PBS 
for 10 min on ice and acetone for 10 min at -20°C, with PBS washings 
between incubations. Subsequent processing of all platelet samples was then 
identical to that described above for tissue culture cells. 
All specimens were examined with Leitz Aristoplan or Zeiss Axiophot 
microscopes equipped with epifluorescence optics. Photographs were taken 
with Tri-X Pan 400 (Kodak) . 
Protein associated with actin filaments and focal contacts 
Immunoblotting 
Samples were separated by SDS-PAGE using 3% stacking and 8% 
separating gels. Proteins were electrophoretically transferred to nitrocellulose 
(0.45 JLm , Schleicher & Schuell, Dassel, FRG) for 1.5 - 3.0 h at 3 - 4 V Icm 
in a buffer containing 25 mM Tris (pH 10), 192 mM glycine and 20% 
methanol. Nitrocellulose sheets were blocked for 6 h or ovemight in blocking 
medium (PBS, 1 % haemoglobin, 0.3% Triton X-lOO, 0.05 % Tween 20, 
0.01 % NaN3) , incubated for 1.5 h at room temperature with antiserum M4 
(1: 1500 in b-Iocking medium) or affinity-purified M4 with or without prior 
preadsorption. For use in immunoblots, affinity-purified M4 and preadsorbed 
affinity-purified M4 were applied at identical final dilutions (1: 120 in buffer 
A). Antibodies bound to immobilized proteins were detected by incubation 
with 0.1 JLCi/ml [ 125 I]protein A (>30 mCi/mg; Amersham Buchler , 
Braunschweig, FRG) . Following the incubations with antiserum and 
[125I]protein A, nitrocellulose sheets were washed repeatedly with PBS 
supplemented with 0.3% Triton X-lOO and 0.05% Tween 20. 
Immunoreactivity was detected by autoradiography of nitrocellulose blots. 
Protein purification 
VASP was purified as described previously (Halbtiigge and Waiter, 1989) 
except that Q-Sepharose FF chromatography was performed at pH 7.5 and 
the CM-cellulose chromatography step was omitted. Protein concentrations 
were determined using the Bradford reagent for purified V ASP and the 
Lowry reagent for cell homogenates with BSA as a standard. Actin was 
purified from porcine skeletal muscle acetone powder essentially as described 
(Jockusch and Isenberg, 1981). Actin concentration was calculated from 
the absorbance at 290 nm (Gordon et al., 1976). 
Cosedimentation assay 
G-Actin (I mg/ml) was allowed to polymerize for 30 min at room 
temperature by the addition of 2 mM MgCI2 and 20 mM KCI (final 
concentrations). VASP was centrifuged at 195000 g for 3 h at 4° C in 
order to remove insoluble particles. After a 30 min co-incubation of F-actin 
and VASP at room temperature (500 JLg/ml actin, 110 JLg/ml V ASP) in 
an imidazole buffer (5 mM imidazole, I mM Tris- HCI [pH 7.2]; 60 mM 
KCI; 2 mM MgCI2; 0.1 mM CaCI2; 1.25 mM EGTA; 0.35 mM ATP; 
0.5 mM DTE), the assay mixture was centrifuged at lOO 000 g for 2 h 
at room temperature in Ultra-Clear tubes (Beckman, Frankfurt, FRG) coated 
with 5 % BSA. Control sedirnentations were performed in which either V ASP 
or actin were omitted . Supematants were carefully aspirated, pellets were 
resuspended in the original assay volume, and equal aliquots of both the 
supernatants and resuspended pellets were then analysed by SDS - PAGE. 
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